Thursday, October 4, 2018: 10:30 AM-11:45 AM
Room: S 206-208
At the conclusion of this session, participants will be able to:
- review the data on the role the indigenous microbiota can play in resistance to colonization and disease to multi-drug resistant organisms.
- analyze the evidence that analysis of the microbiome in an individual patient can provide guidance with formulating specific therapies.
- discuss the impact that therapies that intentionally or unintentionally modify the microbiota can influence susceptibility to infection with MDROs.
Academicians, Clinicians, Epidemiologists, Fellows, Healthcare workers, Hospital administrators, Hospital epidemiologists, Infection preventionists, Infectious diseases pediatricians, Infectious diseases physicians, Investigators, Lab personnel, Medical students and residents, Members-in-training, Microbiologists, Nurses, Pharmacists, Public health practitioners, Researchers, Scientists
Trainee, Transplant ID, Investigative ID, Pediatric ID, Epidemiology and Infection Control, Adult ID
Vincent B. Young, MD, PhD, FIDSA, University of Michigan
L. Clifford McDonald, MD, Centers for Disease Control and Prevention
Maximum of 1.25 hours of AMA PRA Category 1 Credit™
ACPE 1.25 knowledge-based contact hours of pharmacy CE
V. B. Young,
No financial benefit
L. C. McDonald,